Treatment of Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL)
For stage IA NLPHL without risk factors, treat with 30 Gy involved-site radiotherapy alone; for all other stages, treat NLPHL identically to classical Hodgkin lymphoma using combined modality therapy or chemotherapy based on stage and risk factors. 1, 2
Stage IA Without Risk Factors
30 Gy involved-site radiotherapy (ISRT) alone is the standard treatment for stage IA NLPHL patients presenting without clinical risk factors 1, 3, 2. This approach achieves approximately 90% 8-year progression-free survival and nearly 100% 8-year overall survival 4. This is the only scenario where NLPHL treatment differs from classical Hodgkin lymphoma 1, 2.
Risk factors to assess include:
- Large mediastinal mass (>1/3 maximum horizontal chest diameter)
- Age ≥50 years
- Elevated ESR (>50 mm/h without B-symptoms; >30 mm/h with B-symptoms)
- ≥3-4 nodal areas involved
- Extranodal disease
- B symptoms (fever, night sweats, weight loss >10%)
Early-Stage Disease (Stage I-II with Risk Factors)
Treat with combined modality therapy using 2-4 cycles of ABVD followed by 30 Gy ISRT 1, 2. The specific approach depends on whether the disease is classified as limited-stage favorable or intermediate-stage:
- Limited-stage favorable: 2 cycles of ABVD + 20-30 Gy ISRT 2
- Intermediate-stage: 4 cycles of ABVD + 30 Gy ISRT 1, 2
For patients ≤60 years eligible for more intensive treatment with positive interim PET after 2 cycles of ABVD, escalate to 2 cycles of BEACOPPescalated before ISRT 2. This achieves 10-year progression-free survival rates exceeding 70% and 10-year overall survival rates exceeding 90% 4.
Advanced-Stage Disease (Stage III-IV)
Treat with chemotherapy alone, reserving radiotherapy for residual masses >1.5-2.5 cm after chemotherapy 1, 2. Treatment options include:
For patients ≤60 years:
- 6-8 cycles of ABVD (standard approach) 1, 2
- 4-6 cycles of BEACOPPescalated (for more intensive treatment) 2
- Consider R-CHOP as an alternative given CD20 expression 5, 4
For patients >60 years:
- 6-8 cycles of ABVD 1, 2
- Discontinue bleomycin after cycle 2 to reduce pulmonary toxicity 2
- Never use BEACOPP regimens due to excessive toxicity 1, 2
After 2 cycles of ABVD, if interim PET is negative, consider omitting bleomycin in cycles 3-6, especially in elderly patients or those at increased risk for lung toxicity 2.
Key Treatment Principles Specific to NLPHL
The malignant lymphocyte-predominant cells in NLPHL consistently express CD20 but lack CD30 expression, distinguishing them from classical Hodgkin lymphoma 1, 6, 7. This has important therapeutic implications:
- Rituximab monotherapy is highly effective for localized relapses 1, 2, 7
- Addition of anti-CD20 antibodies to standard chemotherapy may improve outcomes, though prospective data are limited 3, 6, 5
- R-CHOP appears effective for advanced-stage disease 5, 4
Relapsed Disease
Always obtain a repeat biopsy before initiating salvage therapy to exclude transformation to aggressive large B-cell lymphoma, which occurs at higher rates than previously recognized 1, 3, 7, 8.
For localized relapses:
For disseminated relapses:
- Conventional chemotherapy ± anti-CD20 antibody 2, 7
- High-dose chemotherapy with autologous stem cell transplantation reserved only for high-risk patients with early recurrence or poor-risk features 1, 2, 7
The salvage approach should be individualized based on time to relapse, extent of disease, and prior treatment 2. NLPHL relapses are salvaged successfully in the majority of cases with less intensive approaches than classical Hodgkin lymphoma 4, 7.
Critical Caveats
The indolent nature and excellent overall survival of NLPHL (nearly mirroring general population life expectancy) means treatment decisions must prioritize minimizing long-term toxicity over aggressive disease control 6, 7, 9. Late relapses are common but manageable 7, 8. The 10-20 year risk of transformation to aggressive lymphoma necessitates long-term surveillance 1, 8.
Given the rarity of NLPHL (only 5% of all Hodgkin lymphoma cases), enrollment in clinical trials or referral to centers with NLPHL expertise is strongly encouraged 6, 5.